natgillin/translations-raw huggingface dataset:
- 17ß-естрадиол и неговите естери и производни.
- Oestradiol 17b and its ester-like derivatives.
- 17ß-естрадиол и неговите естери и производни
- Oestradiol 17b and its ester-like derivatives.
Списък Б:
List B:
Списък Б: забранени субстанции с дерогации
List B: prohibited substances with derogations
It is important to clarify that beta-agonist, although prohibited in general, may be used in certain specific cases.
It is important to clarify that beta-agonist, although prohibited in general, may be used in certain specific cases.
- In Directive 96/22/EC the use of thyrostatic substances, stilbenes, stilbene derivatives, their salts and esters which are on list A of Annex II is prohibited for "animals of all species", meaning for both animals or animal products used for human consumption as well as pets.
- In Directive 96/22/EC the use of thyrostatic substances, stilbenes, stilbene derivatives, their salts and esters which are on list A of Annex II is prohibited for "animals of all species", meaning for both animals or animal products used for human consumption as well as pets.
- The two products on list B in Annex II can be used under certain conditions:
- The two products on list B in Annex II can be used under certain conditions:
· for oestradiol 17 ß and its ester-like derivatives these conditions are set out in Article 5a
· for oestradiol 17 ß and its ester-like derivatives these conditions are set out in Article 5a
· beta agonists can only be used in the cases mentioned in Art 4,par 2
· beta agonists can only be used in the cases mentioned in Art 4,par 2
The proposed modification .
The proposed modification .
The Commission proposes:
The Commission proposes:
- to exclude pet animals from the scope of this directive, which means that prohibitions for the use of certain substances simply do not apply anymore to them;
- to exclude pet animals from the scope of this directive, which means that prohibitions for the use of certain substances simply do not apply anymore to them;
- the hormone oestradiol 17 ß which was temporarily allowed to be used for farm animals for the treatment of foetus maceration or mummification or for pyrometer (Art 5, a) will now be banned completely.
- the hormone oestradiol 17 ß which was temporarily allowed to be used for farm animals for the treatment of foetus maceration or mummification or for pyrometer (Art 5, a) will now be banned completely.
The fourth application for oestrus induction in cattle, horses, sheep or goats had been granted only until October 2006 and had already expired.
The fourth application for oestrus induction in cattle, horses, sheep or goats had been granted only until October 2006 and had already expired.
The reasons behind these proposed modifications are the following:
The reasons behind these proposed modifications are the following:
· pet animals suffering f. ex. from hyperthyroidism could not be treated because of the general ban on thyrostatic substances .There might be other examples of diseases affecting pets and which could not be treated because of a general ban of one of these substances.
· pet animals suffering f. ex. from hyperthyroidism could not be treated because of the general ban on thyrostatic substances .There might be other examples of diseases affecting pets and which could not be treated because of a general ban of one of these substances.
Taking out pet animals from the scope of this directive will allow them to be treated properly and will enhance animal welfare.
Taking out pet animals from the scope of this directive will allow them to be treated properly and will enhance animal welfare.
· for the use of oestradiol 17 ß ,which as recent evidence suggests, is now to be considered as a complete carcinogen, alternatives now exist on the market so that the use of this hormone is redundant and can be banned completely.
· for the use of oestradiol 17 ß ,which as recent evidence suggests, is now to be considered as a complete carcinogen, alternatives now exist on the market so that the use of this hormone is redundant and can be banned completely.
Some considerations :
Some considerations :
There could be an illegal use of some substances which are used and authorised for pets but not for farm animals.
There could be an illegal use of some substances which are used and authorised for pets but not for farm animals.
As the Commission points out experience with such category of substances do not form a major problem for the quality of the products of farm animals because the presentation (in very small packages ) and the price for such medicines is such as to make illegal use unlikely and very unattractive .
As the Commission points out experience with such category of substances do not form a major problem for the quality of the products of farm animals because the presentation (in very small packages ) and the price for such medicines is such as to make illegal use unlikely and very unattractive .
The existence of alternatives for the use of oestradiol 17 ß, namely prostaglandin, is not always sufficiently known amongst primarily the generation of elder veterinarians.
The existence of alternatives for the use of oestradiol 17 ß, namely prostaglandin, is not always sufficiently known amongst primarily the generation of elder veterinarians.
An information campaign would be appropriate now when legislation changes and becomes more compulsory, in order to prevent or reduce unnecessary misuse of substances.
An information campaign would be appropriate now when legislation changes and becomes more compulsory, in order to prevent or reduce unnecessary misuse of substances.
The Commission proposes to remove pet animals from the scope of the Council Directive 96/22/EC what would enable the treatment of these kinds of animals with substances having a thyreostatic action and of beta‑agonists.
The Commission proposes to remove pet animals from the scope of the Council Directive 96/22/EC which would enable the treatment of these kinds of animals with substances having a thyrostatic action and of beta‑agonists.
The ban on these substances will, however, continue for food producing animals.
The ban on these substances will, however, continue for food-producing animals.
Furthermore the Commission proposes to prohibit entirely the use of oestradiol 17ß and its ester-like derivates in food producing animals, putting an end to the various derogations that still exist today.
Furthermore the Commission proposes to prohibit entirely the use of oestradiol 17ß and its ester-like derivates in food-producing animals, putting an end to the various derogations that still exist today.
The Commission intends to simplify and to improve the comprehensibility of Community legislation and to maintain and improve the provisions regarding food security considering that these substances may cause important health problems to human beings.
The Commission intends to simplify and to improve the comprehensibility of Community legislation and to maintain and improve the provisions regarding food security considering that these substances may cause important health problems to human beings.
The draftsman envisages achieving a balance between consumer protection, animal welfare and scientific assessment.
The draftsman envisages achieving a balance between consumer protection, animal welfare and scientific assessment.
Underlining the need to ensure health and welfare of animals by making veterinary medicinal products available, the draftsman welcomes the Commission's proposal to take pet animals out of the scope of the existing legislation on substances having a thyreostatic action and of beta‑agonists.
Underlining the need to ensure health and welfare of animals by making veterinary medicinal products available, the draftsman welcomes the Commission's proposal to take pet animals out of the scope of the existing legislation on substances having a thyrostatic action and of beta‑agonists.
The draftsman notes that a comparison of prices and presentations of products with e.g. a thyreostatic action intended for use on pet animals, shows that it is economically unattractive to use pet products e.g. on cattle.
The draftsman notes that a comparison of prices and presentations of products with e.g. a thyrostatic action intended for use on pet animals, shows that it is economically unattractive to use pet products e.g. on cattle.
Furthermore, these substances could strongly contribute to improving the well-being of pet animals that suffer from diseases like hyperthyroidism.
Furthermore, these substances could strongly contribute to improving the well-being of pet animals that suffer from diseases like hyperthyroidism.
The draftsman welcomes the entire prohibition of the use of oestradiol 17ß and its ester like derivates in food producing animals.
The draftsman welcomes the entire prohibition of the use of oestradiol 17ß and its ester like derivates in food producing animals.
The draftsman pleads for a rapid adoption of the new provisions, explaining that the changes in relation to the banning of use of oestradiol 17ß and its ester-like derivatives are in line with the conclusions of the Commission report
The draftsman pleads for a rapid adoption of the new provisions, explaining that the changes in relation to the banning of use of oestradiol 17ß and its ester-like derivatives are in line with the conclusions of the Commission report
" Report concerning the availability of alternative veterinary medicinal products to those containing oestradiol 17 β or its ester-like derivatives for the treatment of fetal maceration or mummification in cattle, and for the treatment of pyometra ". presented in 2005.
" Report concerning the availability of alternative veterinary medicinal products to those containing oestradiol 17 β or its ester-like derivatives for the treatment of fetal maceration or mummification in cattle, and for the treatment of pyometra ". presented in 2005.
The draftsman proposes to take advantage of these changes to Directive 96/22/EC to amend the definition of therapeutic treatment used therein in order to allow the use of beta-agonists to treat navicular disease and laminitis in equidae raised for purposes other than meat production.
The draftsman proposes to take advantage of these changes to Directive 96/22/EC to amend the definition of therapeutic treatment used therein in order to allow the use of beta-agonists to treat navicular disease and laminitis in equidae raised for purposes other than meat production.
Следователно е уместно, приложното поле на тази Директива да бъде ограничено само върху животните, отглеждани за производство на храни, а забраната, която засяга домашните любимци да отпадне.
(6) It is therefore appropriate to limit the scope of this Directive only to food producing animals and withdraw the prohibition for pet animals.
Следователно е уместно, приложното поле на тази Директива да бъде ограничено само върху животните, отглеждани за производство на храни, а забраната, която засяга домашните любимци да отпадне , а също така да се приспособи дефиницията на терапевтичното лечение.
(6) It is therefore appropriate to limit the scope of this Directive only to food producing animals and withdraw the prohibition for pet animals , as well as to adjust the definition of therapeutic treatment .
(-1) В Член 1 параграф 2, буква б ) се заменя , както следва :
(-1) In Article 1, paragraph 2, point (b) is replaced by the following:
" б " " терапевтично лечение " по смисъла на член 4 от настоящата директива означава предписването на допуснат за продажба препарат за лечението на отделно селскостопанско животно , след преглед от ветеринарен лекар , проблем с плодовитостта - включително прекратяването на нежелана бременност - и в случаите на бета - агонисти , за предизвикване на токолиза при кравите , когато телят , а също и за лечение на дихателни проблеми , заболяване на навикуларната кост и ламинит , както и за предизвикване на токолиза при коне , които не се отглеждат за производство на месо ;"
"(b) 'therapeutic treatment' shall mean the administering - under Article 4 of this Directive - to an individual farm animal of an authorized substance to treat, after examination by a veterinarian, a fertility problem - including the termination of unwanted gestation - and, in the case of beta-agonists, to induce tocolysis in cows when calving as well as to treat respiratory problems, navicular disease and laminitis and to induce tocolysis in equidae raised for purposes other than meat production;"
(1 а ) В член 4, точка 2, буква ( и ) от параграф 1 се заменя , както следва :
(1a) In Article 4, paragraph 2, point (i) is replaced by the following:
"( и ) allyl trenbolone, прилаган орално , или бета - агонисти за коне , които не се отглеждат за производство на месо , при положение , че се използват в съответствие с инструкциите на производителя ;"
"(i) allyl trenbolone, administered orally, or beta-agonists to equidae raised for purposes other than meat production, provided they are used in accordance with the manufacturer's instructions;"
Приложение ІІ (Директива 96/22/ЕО)
ANNEXAnnex II (Directive 96/22/EC)
Забрана за използване на някои вещества с хормонално или тиреостатично действие и някои бета-агонисти в животновъдството
Prohibition on the use in stockfarming of certain substances having a hormonal or thyreostatic action and of beta agonists
Adamos Adamou, Pilar Ayuso, Irena Belohorská, Johannes Blokland, John Bowis, Frieda Brepoels, Magor Imre Csibi, Avril Doyle, Mojca Drčar Murko, Edite Estrela, Jill Evans, Karl-Heinz Florenz, Matthias Groote, Françoise Grossetête, Gyula Hegyi, Jens Holm, Marie Anne Isler Béguin, Caroline Jackson, Dan Jørgensen, Christa Klaß, Eija-Riitta Korhola, Holger Krahmer, Urszula Krupa, Aldis Kušķis, Peter Liese, Jules Maaten, Linda McAvan, Roberto Musacchio, Riitta Myller, Miroslav Ouzký, Vladko Todorov Panayotov, Vittorio Prodi, Frédérique Ries, Dagmar Roth-Behrendt, Guido Sacconi, Karin Scheele, Richard Seeber, María Sornosa Martínez, Antonios Trakatellis, Evangelia Tzampazi, Thomas Ulmer, Marcello Vernola, Anja Weisgerber, Åsa Westlund, Anders Wijkman, Glenis Willmott
Adamos Adamou, Pilar Ayuso, Irena Belohorská, Johannes Blokland, John Bowis, Frieda Brepoels, Magor Imre Csibi, Avril Doyle, Mojca Drčar Murko, Edite Estrela, Jill Evans, Karl-Heinz Florenz, Matthias Groote, Françoise Grossetête, Gyula Hegyi, Jens Holm, Marie Anne Isler Béguin, Caroline Jackson, Dan Jørgensen, Christa Klaß, Eija-Riitta Korhola, Holger Krahmer, Urszula Krupa, Aldis Kušķis, Peter Liese, Jules Maaten, Linda McAvan, Roberto Musacchio, Riitta Myller, Miroslav Ouzký, Vladko Todorov Panayotov, Vittorio Prodi, Frédérique Ries, Dagmar Roth-Behrendt, Guido Sacconi, Karin Scheele, Richard Seeber, María Sornosa Martínez, Antonios Trakatellis, Evangelia Tzampazi, Thomas Ulmer, Marcello Vernola, Anja Weisgerber, Åsa Westlund, Anders Wijkman, Glenis Willmott
относно проекта на регламент на Комисията за изменение на Регламент (ЕО) № 1653/2004 относно стандартен Финансов регламент за изпълнителните агенции съгласно Регламент (ЕО) № 58/2003 на Съвета относно установяването на статута на изпълнителните агенции, отговарящи за някои задачи по управлението на програмите на Общността
on the draft Commission regulation amending Regulation (EC) No 1653/2004 on a standard financial regulation for the executive agencies pursuant to Council Regulation (EC) No 58/2003 laying down the statute for executive agencies to be entrusted with certain tasks in the management of Community programmes
Edit Herczog , комисия по бюджетен контрол
Edit Herczog , Committee on Budgetary Control
(*) Процедура с асоциирана комисия - член 47 от правилника
(*) Procedure with associated committee – Rule 47 of the Rules of Procedure
PE 398.652v02-00
PE 398.652v02-00
ИЗЛОЖЕНИЕ НА МОТИВИТЕ.............................................................................................20
EXPLANATORY STATEMENT..............................................................................................19
ПРИЛОЖЕНИЕ I.....................................................................................................................23
ANNEX I..................................................................................................................................22
ПРИЛОЖЕНИЕ ІІ....................................................................................................................25
ANNEX II.................................................................................................................................23
ПРИЛОЖЕНИЕ III..................................................................................................................27
ANNEX III................................................................................................................................25
СТАНОВИЩЕ на комисията по бюджетен контрол (*)..................................30
OPINION OF THE COMMITTEE ON BUDGETARY CONTROL (*)..................................28
(*) Процедура с асоциирана комисия - член 47 от правилника
(*) Procedure with associated committee - Rule 47 of the Rules of Procedure
– като взе предвид проекта на регламент на Комисията ( SEC(2007)0492 ),
– having regard to the draft Commission regulation ( SEC(2007)0492 ),
– като взе предвид доклада на комисията по бюджети и становището на комисията по бюджетен контрол ( A6‑0068/2008 ),
– having regard to the report of the Committee on Budgets and the opinion of the Committee on Budgetary Control ( A6‑0068/2008 ),
Текст, предложен от Съвета
Text proposed by the Commission
(3a) Фактът, че освобождаването от отговорност на директора на агенцията във връзка с изпълнението на административния бюджет се разграничава от освобождаването от отговорност във връзка с изпълнението от страна на агенцията на оперативните бюджетни кредити по общностни програми, може да се отрази на яснотата на процедурата по освобождаване от отговорност при бързо нарастване на броя на изпълнителните агенции.
(3a) The fact that the discharge to the director of the agency in respect of the administrative budget is distinguished from the discharge in respect of the implementation by the agency of operational approp ria tions relating to Community programmes may endanger the clarity of the discharge procedure in the event of a proliferation of executive agencies.
Die Schaffung jeder neuen Exekutivagentur macht das Entlastungsverfahren komplizierter und beeinträchtigt die Möglichkeiten des Parlaments, die demokratische Aufsicht über die von diesen Einrichtungen verwalteten Mittel wahrzunehmen.
The creation of any new executive agency adds complexity to the discharge procedure and to Parliament's possibilities for democratic oversight over the funds managed by these bodies.
(3б) Предвид различните крайни срокове съответно за решението на Европейския парламент относно освобождаването от отговорност във връзка с общия бюджет - 15 май от година n+2, и за решението за освобождаване от отговорност във връзка с изпълнителните агенции - 29 април от година n+2, всички действащи лица следва да се опитат да избегнат практическите затруднения и да се стремят към хармонизиране на правните основания в бъдеще.
(3b) In consideration of the difference in deadlines for the European Parliament's discharge decision in respect of the general budget, which is 15 May of year n+2, and its discharge decision in respect of the executive agencies, which is 29 April of year n+2, all actors involved should try to avoid difficulties in practice and strive for a harmonisation of the legal bases in the future.
(9) Условията за използването от изпълнителните агенции на службите и офисите на Комисията, междуинституционалните европейски служби и Центъра за преводи за органите на Европейския съюз, създаден с Регламент (ЕО) № 2965/94 на Съвета относно създаване на Център за преводи за органите на Европейския съюз (наричан по-нататък Център за преводи), следва да бъдат изяснени.
(9) The conditions for the use, by the executive agencies, of Commission services and offices, interinstitutional European offices and the Translation Centre for bodies of the European Union established by Council Regulation (EC) No 2965/94 setting up a Translation Centre for bodies of the European Union (hereinafter: Translation Centre) should be clarified.
Следва да бъде добавена разпоредба за подбора на експерти, подобна на въведената в общия Финансов регламент.
A provision for the selection of experts, similar to the one introduced in the general Financial Regulation, should be inserted.
Следва да бъде добавена разпоредба за подбора на експерти, съответстваща на въведената в общия Финансов регламент.
A provision for the selection of experts, corresponding to the one introduced in the general Financial Regulation, should be inserted.
(9а) Следва да се изясни, че управителният съвет или управителният комитет, който се назначава от Комисията и за който следователно Комисията гарантира, че членовете му притежават необходимата квалификация и не са в състояние на конфликт на интереси, носи определени отговорности за бюджета и за въпроси, свързани с контрола, и следователно следва да се отчита пред органа по освобождаване от отговорност.
(9a) It should be clarified that the management board or steering committee - which is appointed by the Commission, the Commission being therefore responsible for ensuring that the board members possess the necessary qualifications and are not subject to any conflict of interest - bears certain responsibilities for budget and control issues and should therefore be accountable to the discharge authority.
Член 9, параграф 4 (Регламент (EО) № 1653/2004)</Article>
Article 9, paragraph 4 (Regulation (EC) No 1653/2004)
1а) В член 9, параграф 4 се заменя със следното:
(1a) In Article 9, the fourth paragraph is replaced by the following:
„ Бюджетните кредити, които са налични към 31 декември и са резултат от целеви приходи, посочени в член 15, се пренасят автоматично.
" The appropriations available at 31 December arising from the assigned revenue referred to in Article 15 shall be carried over automatically.
Наличните бюджетни кредити, които отговарят на пренесените целеви приходи, трябва да бъдат използвани първи.
The appropriations available corresponding to assigned revenue carried over must be used first.
Най-късно да 1 юни на следващата година агенцията уведомява Комисията относно изпълнението на пренесените целеви приходи.
By 1 June of the following year at the latest, the agency shall inform the Commission on the implementation of the assigned revenue carried over.
Комисията изпраща до бюджетния орган най-късно до 15 юли на следващата година обобщен доклад относно използването на целевите приходи на всички изпълнителни агенции."
The Commission shall send a summary report on the usage of the assigned revenue of all executive agencies to the budgetary authority by 15 July of the following year at the latest."
The text of the FR should be in line with the Joint Declaration on Assigned Revenues as agreed by the two arms of the budgetary authority at the Conciliation of 13 July 2007 which "attach a great importance to the monitoring of the assigned revenues, especially to those related to the Community Agencies and ask the Commission to report regularly on their implementation, in particular on the basis of a specific document before the first reading of the budget" -Annex III -point 3.
The text of the FR should be in line with the Joint Declaration on Assigned Revenues as agreed by the two arms of the budgetary authority at the Conciliation of 13 July 2007 which "attach a great importance to the monitoring of the assigned revenues, especially to those related to the Community Agencies and ask the Commission to report regularly on their implementation, in particular on the basis of a specific document before the first reading of the budget" -Annex II -point 3.
Член 13 (Регламент (EО) № 1653/2004)
Article 13 (Regulation (EC) No 1653/2004)
2а) В член 13, параграф 2 се заменя със следното:
(2a) In Article 13, the second paragraph is replaced by the following: